BioAge to present Phase 1 data on BGE-102, targeting inflammation in cardiovascular and retinal diseases on May 8

BioAge Labs will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, a novel oral NLRP3 inflammasome inhibitor. The drug targets inflammation linked to atherosclerotic cardiovascular disease and retinal diseases like diabetic macular edema. The event will feature presentations by BioAge leadership and four medical experts discussing the drug's mechanism and therapeutic potential. Phase 2 data for cardiovascular risk is expected in the second half of 2026, with retinal disease data anticipated in mid-2027.